Comparison 5. Spasmolytics: Global assessment.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Comparing nr (%) of successfully treated patients	22	1983	Risk Ratio (M‐H, Random, 95% CI)	1.49 [1.25, 1.77]
1.1 Alverine	1	107	Risk Ratio (M‐H, Random, 95% CI)	1.20 [0.80, 1.80]
1.2 Cimtetropium/dicyclomine	4	255	Risk Ratio (M‐H, Random, 95% CI)	1.78 [1.15, 2.75]
1.3 Mebeverine	1	80	Risk Ratio (M‐H, Random, 95% CI)	0.42 [0.16, 1.07]
1.4 Otilonium	3	363	Risk Ratio (M‐H, Random, 95% CI)	1.79 [1.31, 2.44]
1.5 Peppermint oil	2	225	Risk Ratio (M‐H, Random, 95% CI)	2.25 [1.70, 2.98]
1.6 Pinaverium	4	308	Risk Ratio (M‐H, Random, 95% CI)	1.66 [1.25, 2.19]
1.7 Pirenzepine	1	24	Risk Ratio (M‐H, Random, 95% CI)	0.83 [0.35, 2.00]
1.8 Propinox	1	75	Risk Ratio (M‐H, Random, 95% CI)	0.77 [0.26, 2.30]
1.9 Scopolamine derivatives	3	426	Risk Ratio (M‐H, Random, 95% CI)	4.43 [0.47, 41.67]
1.10 Trimebutine	2	120	Risk Ratio (M‐H, Random, 95% CI)	0.97 [0.68, 1.38]
2 Comparing scores on global assessment in IBS patients	2	331	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.1 Alvarine	0	0	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.2 Cimetropium/dicyclomine	0	0	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.3 Mebeverine	0	0	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.4 Otilonium	1	271	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.5 Peppermint oil	0	0	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.6 Pinaverium	1	60	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.7 Pirenzepine	0	0	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.8 Propinox	0	0	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.9 Scopolamine derivatives	0	0	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.10 Trimebutine	0	0	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]